SpringWorks Therapeutics is a clinical-stage biopharmaceutical company that develops therapies for rare diseases and cancer. The company was founded in 2017 and is headquartered in Stamford, Connecticut. SpringWorks Therapeutics focuses on developing targeted therapies that address the underlying biology of diseases. The company's lead product candidate, nirogacestat, is being developed for the treatment of desmoid tumors, a rare and debilitating disease. SpringWorks Therapeutics has partnerships with several academic institutions and pharmaceutical companies, including Pfizer and BeiGene.